Author Archives: Scalper1

Intercept Pharma NASH Drug Disappoints In Japan

Biotech Intercept Pharmaceuticals (ICPT) was trading down sharply Wednesday morning after the first Japanese trial of its fatty-liver-disease drug produced mixed results. The midstage trial, conducted by Intercept’s Japanese partner Dainippon Sumitomo Pharma, divided 200 patients with non-alcoholic steatohepatitis (NASH) into three different dosage groups taking obeticholic acid (OCA), along with a placebo group. The endpoint was an two-point

The Zacks Analyst Blog Highlights: Microsoft, Aspen Technology, Citrix Systems, NetSol Technologies and ServiceSource International

For Immediate Release Chicago, IL October 28, 2015 Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks

Facebook, Google To See Upside As Political Ads Shift

Look for Facebook (FB) and Google (GOOGL) to gain as political advertising shifts to digital in the 2016 presidential election cycle, says Citigroup. “In our conversations with industry sources, an overriding theme across all conversations was that Facebook and Google will be the largest recipients of political digital ad spend over the 2016 cycle,” said Citigroup analyst Mark May in a research report. May estimates that $607 million will be spent